Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:24:56 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:LGND - LIGAND PHARMACEUTICAL INC - http://www.ligand.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LGND - Q2.568.02·81.370.170.57+0.200.388.26,1251,84870.59  72.085  70.4394.57  49.2416:13:44Apr 2315 min RT 2¢

Recent Trades - Last 10 of 1848
Time ETExPriceChangeVolume
16:13:44Q70.570.206
16:02:05Q70.570.20308
16:02:02Q70.570.2041
16:01:41Q70.570.20403
16:01:15Q70.570.2059
16:01:13Q70.570.20876
16:01:11Q70.570.20100
16:00:05Q70.570.2020
16:00:05Q70.570.20132
16:00:05Q70.570.20115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-23 08:31U:LGNDNews ReleaseLigand to Report First Quarter 2024 Financial Results on May 7, 2024
2024-04-08 08:15U:LGNDNews ReleaseLigand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
2024-04-03 09:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI(TM)
2024-03-05 16:01U:LGNDNews ReleaseLigand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
2024-03-04 08:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 07:00U:LGNDNews ReleaseLigand Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-22 16:01U:LGNDNews ReleaseLigand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa(TM)
2024-02-16 08:00U:LGNDNews ReleaseLigand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
2024-02-13 16:01U:LGNDNews ReleaseLigand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-02-01 17:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-10 19:30U:LGNDNews ReleaseHenlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
2024-01-05 16:30U:LGNDNews ReleaseU.S. Food and Drug Administration Approves ZELSUVMI ¢ „ ¢ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
2023-12-12 12:01U:LGNDNews ReleaseLigand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
2023-12-12 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
2023-12-06 16:02U:LGNDNews ReleaseLigand to Host Investor and Analyst Day on December 12, 2023 in New York City
2023-12-01 08:20U:LGNDNews ReleasePalvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN ¢ „ ¢ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
2023-11-28 09:01U:LGNDNews ReleaseSermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
2023-11-08 16:01U:LGNDNews ReleaseLigand Reports Third Quarter 2023 Financial Results
2023-11-06 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
2023-11-01 08:00U:LGNDNews ReleaseLigand Acquires Royalty on Sanofi ¢ € ™s TZIELD ‚ ® for $20 Million